Quadriceps autograft may be a viable option for revision ACL reconstruction
Key takeaways:
- Quadriceps autograft outperformed bone-patellar tendon-bone in patient-reported outcomes at 6 months and 1 year.
- Quadriceps autograft had a return to sport rate 1.4 months sooner vs. bone-patellar tendon-bone.
NEW ORLEANS — An all-soft tissue quadriceps autograft may be a viable graft option in revision ACL reconstruction with similar outcomes, return to sport and complication rates as bone-patellar tendon-bone autograft, according to results.
Joseph Brinkman, MD, and colleagues retrospectively collected patient-reported outcomes with Lysholm and IKDC scores among 58 high school- or college-level athletes who underwent a first-time revision ACL reconstruction with either a bone-patellar tendon-bone autograft (n=26; BTB) or an all-soft tissue quadriceps tendon autograft (n=32). Researchers also collected return to sport rate and timeline, as well as complications, including retears.


“In terms of patient-reported outcomes, we found the quadriceps tendon outperformed the BTB at the 6-month and 1-year time points,” Brinkman said. “Importantly, however, this difference disappeared at the 2-year follow-up.”
Brinkman noted there was one retear in the quadriceps tendon group and two retears in the BTB group, which was not significantly different. He added that there was also no significant difference in the risk of arthrofibrosis between the two groups.
“In terms of return to sport rate, we did not find any significant differences in terms of overall return or return to the same level,” Brinkman said. “However, when we looked at time to return, we found that the quadriceps group got to sport on average 1.4 months sooner than the BTB group and this was found to be statistically significant.”